HLX 43
Alternative Names: Anti-PD-L1 ADC; HLX-43Latest Information Update: 23 Aug 2025
At a glance
- Originator Shanghai Henlius Biotech
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cervical cancer; Liver cancer; Non-small cell lung cancer; Squamous cell cancer
- Phase I/II Solid tumours
Most Recent Events
- 23 Aug 2025 9448363- Added clinical data, approval info in KDM and HE, Added planned trial info in KDM and HE
- 19 Aug 2025 Shanghai Henlius Biotech plans a phase II trial for Adenocarcinoma (Late-stage disease, Metastatic disease) in China (IV), in August 2025 (NCT07115485)
- 07 Aug 2025 US FDA approves IND application for HLX43 (Injection) in Malignant-thymoma